Are Dividend Giants BHP Billiton plc, GlaxoSmithKline plc And HSBC Holdings plc Worth A Buy?

Are Dividend Giants BHP Billiton plc (LON:BLT), GlaxoSmithKline plc (LON:GSK) And HSBC Holdings plc (LON:HSBA) Worth A Buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These dividend giants all pay out huge yields that are great for any portfolio. As you can see in the table below all three companies pay more than 6% dividend yield against a FTSE 100 average yield of 4%. Income stocks are becoming a popular addition to many portfolios and should be part of every investor’s research. The three companies listed below are some of the UK’s most popular stocks. 

  Dividend
Yield
Dividend
Cover
BHP 11.7% 0.4
GlaxoSmithKline 6.17% 0.83
HSBC 6.3% 1.58

BHP Billiton

BHP Billiton (LSE: BLT), like many other commodity-based companies, has had a year to forget. Commodity prices are falling ever lower and the company has recently had an environmental disaster in Brazil where 13 people died in a dam burst. The company pays a huge dividend that is coming under threat due to declining revenues and a possible $3.5bn fine for the dam burst in Brazil. 

The dividend cover of 0.4 is less than reassuring, too, and commodity prices don’t look like shooting higher any time soon. Investors that buy the shares now and hold for the long term may well be rewarded well, but should expect short term pain first. 

GlaxoSmithKline

GlaxoSmithKline’s (LSE: GSK) share price has also been under increased pressure, due to blockbuster drugs coming off patent. This has come as a slight surprise to many, as Glaxo has an exiting pipeline of new drugs that should boost company earnings and fill the earnings gap. City analysts forecast strong earnings growth in 2016 and 2017, which should also give strength to its dividend.

At a current yield of 6.1% it looks a solid bet for the next few years, with big growth prospects for such a large company. 

HSBC

HSBC (LSE: HSBA) currently has a P/E ratio of just over 9.5, which implies the company is undervalued and has scope for growth. This growth should be provided by HSBC’s emerging market business and 2016 looks like it may be a good year in these emerging countries. China and India have both had good growth numbers come out in the last few weeks which is encouraging. The company has also identified billions worth of savings that should do wonders for the bank going forward. 

The three companies listed here all offer various risk profiles that should always be taken into account before investing. BHP is the ‘higher risk’ company, due to the declining commodities environment, and its dividend may well have to be cut to conserve cash. It does however offer the highest yield in the FSTE 100,  so for brave investors that believe in the company this could well be the buying opportunity of the decade. GlaxoSmithKline and HSBC are ‘lower risk’ plays, offering solid income with growth prospects too. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »